{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:43:36Z","timestamp":1760377416422,"version":"build-2065373602"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>PICTURE (NCT04012931) was a phase 2, open-label, single-arm, multicenter study evaluating pharmacokinetics (PK), safety, tolerability and antiviral activity of oral rilpivirine in combination with other antiretroviral therapy (ART) in children living with HIV-1 with virologic suppression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Children (\u22652 to &lt;12 years, \u226510\u2009kg) living with HIV-1, virologically suppressed (HIV-1 RNA &lt;50 copies\/mL) on a stable ART were enrolled. Weight-based rilpivirine [25\u2009mg once-daily (qd) for \u226525\u2009kg, 15\u2009mg (6\u2009\u00d7\u20092.5\u2009mg) qd for 20\u2009kg to &lt;25\u2009kg and 12.5\u2009mg (5\u2009\u00d7\u20092.5\u2009mg) qd for 10 to &lt;20\u2009kg in film-coated or investigational dispersible tablet formulations] was administered orally in combination with background ART for 48 weeks. The primary objectives were evaluation of rilpivirine steady-state PK, determination of an appropriate weight-based dose, and safety and tolerability when combined with other ARTs. Results of the primary (week 24) and final (week 48) analyses are presented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 40 participants screened, 26 (65%) were enrolled and treated with rilpivirine. All participants completed the week 48 visit and were included in the final analysis. PK parameters were observed to be in the target range for all rilpivirine weight-based doses. Through week 48, 19\/26 (73.1%) participants had \u22651 adverse event; all grade 1\u20132 and none were treatment related. All 26 participants (100%) receiving rilpivirine in combination with ART remained virologically suppressed at both weeks 24 and 48. Adherence to treatment was 98.99%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Rilpivirine in combination with background ART was well-tolerated and maintained virologic suppression from baseline through week 48 in the studied population of children living with HIV-1. Rilpivirine exposure was within the target range for all doses.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004943","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T21:05:04Z","timestamp":1755637504000},"page":"1072-1078","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE Study"],"prefix":"10.1097","volume":"44","author":[{"given":"Johan","family":"Lombaard","sequence":"first","affiliation":[{"name":"Josha Research, Bloemfontein, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Ssali","sequence":"additional","affiliation":[{"name":"Joint Clinical Research Centre, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Visal","family":"Moolasart","sequence":"additional","affiliation":[{"name":"Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Guarino","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Universitaria Federico II, Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Badolato","sequence":"additional","affiliation":[{"name":"Istituto Molecolare Angelo Nocivelli dell\u2019Universita\u2019 degli Studi di Brescia, ERN-RITA, ASST Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Bernardi","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarida","family":"Tavares","sequence":"additional","affiliation":[{"name":"CHSJ\u2014Hosp. Sao Joao, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Fortuny","sequence":"additional","affiliation":[{"name":"Hosp. Sant Joan De Deu, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Aurpibul","sequence":"additional","affiliation":[{"name":"Research Institute for Health Sciences, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supattra","family":"Rungmaitree","sequence":"additional","affiliation":[{"name":"Siriraj Hospital Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica","family":"Van Solingen-Ristea","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Van Eygen","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Van Hemelryck","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Russu","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kurosawa","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minaka","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Vanveggel","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Van Landuyt","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"R3-20251013","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/FTD.0000000000000637","article-title":"Optimizing pediatric dosing recommendations and treatment management of antiretroviral drugs using therapeutic drug monitoring data in children living with HIV.","volume":"41","author":"Waalewijn","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R4-20251013","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3018(21)00265-4","article-title":"Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries.","volume":"8","author":"Han","year":"2021","journal-title":"Lancet HIV"},{"key":"R5-20251013","doi-asserted-by":"crossref","first-page":"207","DOI":"10.31887\/DCNS.2020.22.3\/blutz","article-title":"Neurobiology of cannabinoid receptor signaling.","volume":"22","author":"Lutz","year":"2020","journal-title":"Dialogues Clin Neurosci"},{"key":"R6-20251013","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1016\/S2352-3018(19)30193-6","article-title":"Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.","volume":"6","author":"Penazzato","year":"2019","journal-title":"Lancet HIV"},{"key":"R10-20251013","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/507526","article-title":"Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression.","volume":"43","author":"Bangsberg","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R11-20251013","doi-asserted-by":"crossref","first-page":"e68174","DOI":"10.7554\/eLife.68174","article-title":"Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy.","volume":"10","author":"Pasternak","year":"2021","journal-title":"eLife"},{"key":"R12-20251013","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1310\/LNHD-K1R7-HQP5-HJCQ","article-title":"Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence.","volume":"5","author":"Weiser","year":"2004","journal-title":"HIV Clin Trials"},{"key":"R13-20251013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e31824d006e","article-title":"Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.","volume":"60","author":"Cohen","year":"2012","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"key":"R14-20251013","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2165\/11597680-000000000-00000","article-title":"Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.","volume":"71","author":"Penazzato","year":"2011","journal-title":"Drugs"},{"key":"R15-20251013","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/INF.0000000000001275","article-title":"Rilpivirine as a treatment for HIV-infected antiretroviral-na\u00efve adolescents: week 48 safety, efficacy, virology and pharmacokinetics.","volume":"35","author":"Lombaard","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20251013","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1017\/S0029665113003649","article-title":"Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.","volume":"73","author":"Pertwee","year":"2014","journal-title":"Proc Nutr Soc"},{"key":"R18-20251013","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/INF.0000000000004828","article-title":"Pharmacokinetics, safety and antiviral activity of rilpivirine in antiretroviral-na\u00efve children with HIV \u22656 to <12 years old: week 48 and final analysis of cohort 2 from the open-label, phase 2 PAINT study.","volume":"44","author":"Lombaard","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20251013","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3851\/IMP3198","article-title":"Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents.","volume":"23","author":"Jantarabenjakul","year":"2018","journal-title":"Antivir Ther"},{"key":"R20-20251013","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as first- or second-line treatment for HIV-1 infection in children.","volume":"385","author":"Turkova","year":"2021","journal-title":"N Engl J Med"},{"key":"R21-20251013","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/mp.2012.90","article-title":"Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure.","volume":"18","author":"Hill","year":"2013","journal-title":"Mol Psychiatry"},{"key":"R22-20251013","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1152\/physrev.00004.2003","article-title":"Role of endogenous cannabinoids in synaptic signaling.","volume":"83","author":"Freund","year":"2003","journal-title":"Physiol Rev"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:10:06Z","timestamp":1760375406000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004943","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"type":"print","value":"0891-3668"},{"type":"electronic","value":"1532-0987"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}